Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other cancers. Its lead candidate, palazestrant, is an oral small molecule designed to block and degrade the estrogen receptor; it is being studied as a monotherapy and in… From the company’s description.
In fiscal 2025, Olema Pharmaceuticals, Inc. reported a net loss of $162.45M. Operations used $146.72M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Olema Pharmaceuticals, Inc. does
In the company’s own words
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other cancers. Its lead candidate, palazestrant, is an oral small molecule designed to block and degrade the estrogen receptor; it is being studied as a monotherapy and in combinations for ER-positive, HER2-negative advanced or metastatic breast cancer. Olema’s second clinical-stage candidate, OP-3136, is an oral inhibitor of the KAT6 epigenetic target being evaluated in breast and other cancers. The company’s research also explores additional targeted therapies for breast cancer, while clinical collaborations support development of its candidates. Olema owns worldwide development and commercialization rights to palazestrant and OP-3136, relies on third parties to manufacture its candidates, and has no products approved for commercial sale. Its pipeline includes two pivotal Phase 3 trials of palazestrant: OPERA-01 as a monotherapy and OPERA-02 with ribociclib. In 2025, the company initiated a Phase 1 trial of OP-3136 and OPERA-02. Its website is www.olema.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1750284
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Olema Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Olema Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Olema Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Olema Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Olema Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Olema Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”